# The WavelinQ™ Arterio-Venous Endovascular Fistula: A Global, Post-Market Investigation

> **NCT04626427** · NA · TERMINATED · sponsor: **C. R. Bard** · enrollment: 21 (actual)

## Conditions studied

- End Stage Kidney Disease
- Chronic Kidney Diseases
- Kidney Failure
- Kidney Insufficiency
- Kidney Disease, Chronic
- AV Fistula
- Fistulas Arteriovenous

## Interventions

- **DEVICE:** WavelinQ™ EndoAVF System

## Key facts

- **NCT ID:** NCT04626427
- **Lead sponsor:** C. R. Bard
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-23
- **Primary completion:** 2022-06-15
- **Final completion:** 2022-06-15
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Due to shifting post-pandemic clinical landscape, concurrent study (NCT04634916) to provide results on analogous endpoints in advance of current projections
- **Last updated:** 2025-01-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04626427

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04626427, "The WavelinQ™ Arterio-Venous Endovascular Fistula: A Global, Post-Market Investigation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04626427. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*